The disruption of critical genes is a hallmark of cancer. Identification of these genes is a first step to understanding the disease, but once the genes have been identified, elucidating changes in their expression levels can aid in identifying biomarkers with the potential to predict disease progression and point to appropriate treatments. Approaches to determine the relevance of prospective gene expression signatures for the identification of important disease phenotypes will be discussed. Our webinar panelists, both cancer experts, will describe their research and how they have translated their own discoveries into validated gene expression signatures using arrays.
During the webinar, the speakers will:
• Describe their experimental approaches to validating genetic signatures
• Share their findings demonstrating the potential correlation of gene expression biomarkers with known cancer phenotypes
• Address the most critical factors when considering validating gene expression data
• Answer your questions live on air!
Paul “Mickey” Williams, Ph.D.
Dr. Williams earned a B.A. in biology and psychology and a Ph.D. in microbiology at the University of Virginia in Charlottesville. He did postdoctoral work in the molecular biology of cell differentiation at Stanford University, in Stanford, California. During his 13 years at Genentech, he developed novel assays to support clinical studies and identify new therapeutic targets. Dr. Williams was the author of the first quantitative “real-time” PCR papers and contributed to the development of this powerful technology. Following his work at Genentech, Dr. Williams was a senior research group leader in the Genomics and Oncology Department at Roche Molecular Diagnostics. At Roche, he led the research effort and managed two large multinational clinical assay studies: The MILE Study (microarray innovations in leukemia) and the Roche-led collaboration with the LLMPP (leukemia and lymphoma molecular profiling project). Dr. Williams joined Frederick National Laboratories for Cancer Research in 2010, where he is director of the Molecular Characterization Laboratory, a recently established program developing and using state-of-the-art genomic technologies for clinical research. The goal is to assist in the development and application of well-characterized validated clinical assays to support cancer patient management. He has published over 50 manuscripts and is an inventor on over 30 issued U.S. patents. Dr. Williams is a member of the American Society of Hematology and the American Society of Clinical Oncology.
Timothy J. Triche, M.D., Ph.D.
University of Southern California
Los Angeles, CA
Dr. Triche received his Bachelor’s degree from Cornell University in Ithaca, New York and his medical degree and Ph.D. from the Tulane University School of Medicine in New Orleans. He completed an internship and his medical residencies at Washington University Medical School/Barnes Hospital in St. Louis. Dr. Triche was senior staff fellow in the Laboratory of Pathology at the National Cancer Institute (NCI) of the National Institutes of Health, Bethesda, Maryland, before moving to Children’s Hospital Los Angeles, where he is now director of the Center for Personalized Medicine and former chair of the Department of Pathology & Laboratory Medicine and pathologist-in-chief. He is also currently vice chair of the Department of Pathology and professor of pathology and pediatrics at the Keck School of Medicine. Some of his major areas of research interest include biology and molecular genetics of childhood and adult cancer; correlation of sarcoma gene expression profiles and clinical outcomes; identification and validation of diagnostic, prognostic and therapeutic gene targets; and the mechanisms of action of chimeric genes in childhood sarcomas. Dr. Triche is the author of more than 200 peer-reviewed publications, 176 abstracts, and 39 book chapters and has been the recipient of several large-scale grants from the NCI and U.S. Department of Defense to develop genomic profiles of childhood cancer, using microarray and next generation sequencing technology. He received an Outstanding Service Award from the United States Public Health Service for his work on childhood cancer and has been named as one of the “Best Doctors in America” since 2004, among other awards and invited professorships.
Moderator: Sean Sanders, Ph.D.
Dr. Sanders did his undergraduate training at the University of Cape Town, South Africa, and his Ph.D. at the University of Cambridge, UK, supported by the Wellcome Trust. Following postdoctoral training at the National Institutes of Health and Georgetown University, Dr. Sanders joined TranXenoGen, a startup biotechnology company in Massachusetts working on avian transgenics. Pursuing his parallel passion for writing and editing, Dr. Sanders joined BioTechniques as an editor, before joining Science/AAAS in 2006. Currently Dr. Sanders is the Editor for Custom Publishing for the journal Science and Program Director for Outreach.
For more information on products/technologies related to this webinar, go to: www.affymetrix.com/genomics